Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0G6DF
|
|||
| Former ID |
DIB012868
|
|||
| Drug Name |
HMPL-004
|
|||
| Synonyms |
Nuclear factor kappa B inhibitor (oral, IBD/ulcerative colitis/Crohns disease), Hutchson Medipharma; TNF alpha ligand inhibitor (oral, IBD/ulcerative colitis/Crohns disease), Hutchson Medipharma; IL-1 beta modulator (oral, IBD/ulcerative colitis/Crohns disease), Hutchson Medipharma; IL-6 antagonist (oral, IBD/ulcerative colitis/Crohns disease), Hutchson Medipharma
Click to Show/Hide
|
|||
| Indication | Inflammatory bowel disease [ICD-11: DD72; ICD-10: K50-K52] | Phase 3 | [1] | |
| Company |
Hutchison Medipharma Enterprises Ltd
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | Inflammation pathogenesis (IP) | Target Info | Antagonist | [2] |
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01882764) A Phase III Maintenance Placebo Controlled Maintenance Trial Of HMPL-004 in Subjects With Mild to Moderate Ulcerative Colitis. U.S. National Institutes of Health. | |||
| REF 2 | Clinical pipeline report, company report or official report of Hutchison Medi Pharma. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.